Strategic M&A for Growth: Deal Thesis, Synergy Math, and When to Walk Away

An acquisition creates value for the buyer only if the target is worth more inside the buyer than the buyer pays for it. That sounds obvious, but the price of a contested deal is set by the most optimistic bidder, and the premium over the target's market value is paid in full at closing while the savings and extra sales that justify it arrive over years, if they arrive at all.

This guide covers the buyer's side of the decision: writing a deal thesis, choosing among deal types, valuing synergies against the premium, and setting a price at which you stop bidding. Checking the target is covered in our M&A due diligence guide, and running the combined company after closing is in our post-merger integration playbook. Investors trading announced deals should read the merger arbitrage guide.

Start with a deal thesis

A deal thesis is a short written answer to three questions: what the combined company can do that the two companies cannot do apart, how much that is worth, and why buying is better than building or partnering. It should fit on a page, and it should name the specific costs that disappear or the specific customers who buy more.

A thesis that says "expand into the Southeast" or "add AI capability" states a goal. A thesis would say "close 11 of the target's 19 distribution centers because our network already covers those ZIP codes, saving about $9 million a year." That version can be tested in diligence and tracked after closing.

Before a target is on the table, compare the deal with the alternatives. Building the capability in-house is slower but pays no premium. A licensing deal, joint venture, or minority stake can test the thesis before you commit. If a build plan would take three years and cost less than the premium, the deal has to be worth those three years. Our capital allocation guide covers how to rank an acquisition against buybacks, capital spending, and debt reduction.

Deal types and what each one pays for

The type matters because it tells you which kind of synergy you are paying for. Cost synergies in a scale deal are within the acquirer's control: it can close the duplicate office. Revenue synergies depend on customers choosing to buy more. McKinsey's review of 160 deals in "Where mergers go wrong" found that almost 70% of mergers missed their revenue synergy estimates, while cost synergy estimates were more often met. The study is old, but no later public dataset we know of reverses that pattern.

Capability deals are the hardest to value because the asset walks out the door each evening. Retention agreements help, but the thesis should say what the deal is worth if a third of the key engineers leave within two years.

Valuing synergies against the premium

The control premium is the amount paid above the target's standalone value, which for a public company is its unaffected share price. It is a transfer to the target's shareholders at closing. Synergies are the buyer's way of earning it back.

Premiums are larger than many first-time acquirers expect. In a Goldman Sachs analysis summarized in Electronic Arts' 2025 merger proxy, the median premium in 179 all-cash acquisitions of US public companies worth $5 billion or more, announced from July 2015 to September 2025, was 32% over the last undisturbed price, with the 25th and 75th percentiles at 20% and 51%. The same proxy measured about 480 deals of $500 million or more against the target's highest close in the prior 52 weeks and found a median premium of only 6%. Boards and sellers often anchor on that 52-week high.

Illustration: an acquirer bids for a public company with an unaffected equity value of $400 million, no net debt, $300 million of revenue, and $40 million of EBITDA (10 times EBITDA). The acquirer's plan:

• Cost synergies of $15 million a year before tax, reaching 30%, 75%, and 100% of that run rate in years one to three.
• Revenue synergies worth $9 million a year of extra operating profit, reaching 0%, 25%, 60%, and 100% in years one to four.
• One-time integration costs of $22 million, spent 60/30/10 over three years and deductible.
• Deal fees of $10 million, a 25% tax rate, no growth in synergies once they reach full run rate.
• Discount rates of 9% for cost synergies and 12% for revenue synergies, since the second kind is less certain.

Now set that against the price at three points in the Goldman range:

Value to buyer is net synergy value minus the premium and the $10 million of fees. At the 32% median, the target's shareholders receive $128 million of the $145.2 million of net synergy value, or 88%, before a single cost is removed. The buyer's shareholders keep $7.2 million, and only if the revenue synergies arrive on schedule.

Turn the question around and ask how much synergy the premium implies. If integration costs scale with the savings (about $1.47 of one-time cost per $1 of run-rate savings in this plan), each $1 million of run-rate cost savings is worth about $6.7 million today. Covering a 32% premium plus fees with cost savings alone requires about $20.5 million a year before tax, which is 6.8% of the target's revenue and 51% of its EBITDA. Put that number next to the target's actual cost base. If the overlapping costs you can name add up to $12 million, the bid is relying on revenue synergies or on hope.

Then stress the plan. Suppose savings arrive a year late (10%, 40%, 75%, 100% over four years), integration costs run 30% over budget, and the revenue synergies never show up. The present value of cost synergies falls to $107.9 million and integration costs rise to $18.9 million. The deal is worth -$49.0 million to the buyer at a 32% premium and -$1.0 million at 20%. The integration playbook shows how the cumulative savings curve shifts when delays happen, and Bain's 2026 midyear M&A report puts the bulk of run-rate cost synergies in large deals at 24 to 36 months after closing.

The accounting shows the same thing later. Most of the premium is booked as goodwill and intangible assets, and if the combined business underperforms, those are written down. Kraft Heinz, formed by a $46 billion merger in 2015 built on cost cuts, recorded about $15.4 billion of impairments in February 2019, including $7.1 billion of goodwill.

Cash, stock, and earnouts

How you pay changes who carries the synergy risk.

• Cash: the acquirer's shareholders carry all of it. If synergies fall short, the target's former owners have already been paid.
• Stock: the target's shareholders become owners of the combined company and share any shortfall in proportion to their stake. Illustration: if the acquirer is worth $1,600 million and pays the $528 million price entirely in new shares, the target's holders own about 24.8% of the combined company, so a $50 million shortfall in synergy value costs them about $12.4 million and the acquirer's original holders the rest. Stock also dilutes the buyer, and if the buyer thinks its own shares are undervalued, it is paying with an expensive currency.
• Earnouts: part of the price depends on the target hitting revenue or profit goals after closing. They are common in private deals, where SRS Acquiom data summarized by DealLawyers show earnouts in 24% of 2025 transactions. They bridge disagreement about the target's own forecast but invite disputes over how the buyer ran the business, so define the metric, the accounting rules, and the buyer's operating obligations in the agreement.

Debt-funded cash deals add a second question: can the combined company carry the debt if synergies are late? Our guide to business borrowing capacity covers coverage ratios and rate-shock tests, and the leveraged buyout guide shows how financial buyers structure deals when there are no synergies to count on.

Setting a walk-away price and bidding against it

Write the walk-away number down before the first bid, and have the board approve it. A workable rule is standalone value plus a share of the cost synergies you can list line by line, with revenue synergies treated as upside the buyer keeps rather than something it pays for. In the illustration, paying for no more than the cost-only net value (after fees) caps the premium at $90.9 million, or 22.7%. Including revenue synergies would allow 33.8%, which leaves nothing for execution risk.

Habits that keep the number from drifting:

• Separate the people who value the deal from the people whose bonus depends on closing it. A deal team that has worked on a target for six months will find reasons for another 5%.
• Do not change the valuation method mid-process. Switching from a DCF to "strategic value" or to a precedent-transaction multiple after losing a round is how the price rises without the thesis changing.
• Price what you learn in diligence. A quality-of-earnings adjustment of $2 million of EBITDA at 12 times is $24 million off the price, as our due diligence guide shows with a worked example.
• Count the cost of losing. Losing an auction has no cost beyond fees already spent. Overpaying costs the premium plus years of management attention.
• Ask what a financial buyer would pay. If a private equity fund with no synergies bids close to your number, you are paying away most of your synergies.

For private companies, our valuation guide covers the standalone methods, and the business succession guide covers the seller's side of the same negotiation.

Antitrust and HSR in 2026

Any US deal above the Hart-Scott-Rodino thresholds needs a premerger filing and a waiting period before closing, which affects both timing and the risk that a deal is blocked. For transactions closing on or after February 17, 2026, the FTC's 2026 figures are:

The expanded HSR form the FTC introduced in February 2025 was vacated by a federal district court in Texas on February 12, 2026, according to Kirkland & Ellis, and filers are back on the older form. The appeal is on hold through December 31, 2026 while the agencies consider a revised form, per Latham & Watkins; a new proposal is expected by year-end, so check the current form before filing.

Substantive review follows the 2023 Merger Guidelines, which FTC Chairman Andrew Ferguson confirmed in February 2025 remain in effect. Most filings clear without a deep review: in fiscal 2025 the agencies issued second requests in 41 of 1,944 adjusted transactions, about 2.1%, according to the FTC and DOJ annual HSR report. A horizontal deal between two of a handful of competitors is the kind that draws one. If yours might, build the review time into the timetable and the reverse termination fee, and remember that divestitures demanded by regulators can remove some of the synergies you priced in.

Until the waiting period ends, the buyer cannot run the target. Planning integration is allowed; approving the target's ordinary business decisions is not, and the due diligence guide covers the gun-jumping rules.

Before you make an offer

1. Write the thesis in one page, with named cost lines and named customer groups.
2. Compare the deal with building, licensing, or a minority stake.
3. Value cost and revenue synergies separately, net of one-time costs, with a higher discount rate for revenue.
4. Work out how much run-rate synergy the premium implies and compare it with the target's cost base.
5. Run a stress case with a one-year delay, a cost overrun, and no revenue synergies.
6. Set the walk-away price, get board approval, and decide in advance who can change it and on what evidence.
7. Choose cash, stock, or an earnout based on who should carry the synergy risk.
8. Check HSR reportability and the antitrust risk, and plan the timeline and termination fees around it.
9. Name the integration leader before signing, so the people who will deliver the synergies have tested the numbers. The integration playbook picks up from there.

If AI tools are part of your diligence process, our guide to AI in M&A due diligence covers what they can and cannot check.

This guide is for informational purposes only and does not constitute investment, legal, tax, or accounting advice. Thresholds, fees, and regulatory positions are as of September 2026 and change over time; the illustrations use assumed numbers and are not forecasts. Consult qualified M&A counsel, antitrust counsel, and financial advisers before making an offer.